References
- Ravid R . Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection. J. Neurol. Sci.283, 119–126 (2009).
- Fasano M , AlberioT. Biomarkers of Parkinson‘s disease. In: Advances in Parkinson‘s Disease Management. FriedmanJH (Ed.). Future Medicine Ltd, London, UK, 18–29 (2012).
- Fasano M . Biochemistry of Parkinson‘s disease – insights from cellular models, animal models and human tissue specimens obtained by autopsy. FEBS J.279(7), 1145 (2012).
- Ravid R . Standard operating procedures, ethical and legal regulations in BTB (brain/tissue/bio) banking: what is still missing? Cell Tissue Bank9, 121–137 (2008).
- Ravid R , FerrerI. Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson‘s disease. FEBS J.279(7), 1167–1176 (2012).
- Baker M . Biorepositories: building better biobanks. Nature 6, 486(7401), 141–146 (2012).
- Fagan AM , ShawLM, XiongCet al. Comparison of analytical platforms for cerebrospinal fluid measures of Aβ1–42, total tau and p-tau181 for identifying Alzheimer‘s disease amyloid plaque pathology. Arch. Neurol.68(9), 1137–1144 (2011).
- Vos S , van RossumI, BurnsLet al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol. Aging33(10), 2272–2281 (2012).
- Schoonenboom NS , ReesinkFE, VerweyNAet al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 3, 78(1), 47–54 (2012).
- Mattsson N , RosénE, HanssonOet al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology78(7), 468–476 (2012).
- Ferrer I . Early involvement of the cerebral cortex in Parkinson‘s disease: convergence of multiple metabolic defects. Prog. Neurobiol.88(2), 89–103 (2009).
- Ravid R , FerrerI. Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson‘s disease. FEBS J.279(7), 1167–1176 (2012).
- Wu Y , LeW, JankovicJ. Preclinical biomarkers of Parkinson disease. Arch. Neurol.68(1), 22–30 (2011).
- Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol.95(4), 629–635 (2011).
- Frasier M , ChowdhuryS, EberlingJ, ShererT. Biomarkers in Parkinson‘s disease: a funder‘s perspective. Biomark. Med.4(5), 723–729 (2010).
- Alberio T , FasanoM. Proteomics in Parkinson‘s disease: an unbiased approach towards peripheral biomarkers and new therapies. J. Biotechnol.156(4), 325–337 (2010).
- Park YM , KimJY, KwonKHet al. Profiling human brain proteome by multi-dimensional separations coupled with MS. Proteomics6(18), 4978–4986 (2006).
- Kwon KH , ParkGW, KimJYet al. Island clustering analysis for the comparison of the membrane and the soluble protein fractions of human brain proteome. Proteomics8(6), 1149–1161 (2008).
- Cruz-Sánchez FF , RavidR, CuznerML. The European Brain Bank Network (EBBN) and the need of standardized neuropathological criteria for brain tissue cataloguing. In: Neuropathological Diagnostic Criteria for Brain Banking, European Union Biomedical and Health Research. Cruz-SánchezFF, CuznerML, RavidR(Eds) . IOS Press, Amsterdam, The Netherlands, 1–3 (1995).
- Ravid R , GrinbergLT. How to run a brain bank – revisited. Cell Tissue Bank9(3), 149–150 (2008).
- Ferrer I , ArmstrongJ, CapellariSet al. Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol.17(3), 297–303 (2007).
- Ravid R . Methodological considerations of the establishment of a brain bank for psychiatric research; the Amsterdam and European experience. In: The Post-Mortem Brain in Psychiatric Research. AgamG, BelmakerRH, EverallI(Eds) . Kluwer Academic Publishers, MA, USA, 11–19 (2002).
- Karen M eir, Eoin F Gaffney, Daniel Simeon-Dubach et al. The human face of biobank networks for translational research. Biopreserv. Biobank.9(3), 279–285 (2011).
- Crystal HA , DaviesP. Towards a biomarker for Alzheimer‘s disease: some progress, but still a long way to go. Neurology70(8), 586–587 (2008).
- Mosconi L , RinneJO, TsuiWH. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer‘s parents. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2012.03.002 (2012) (Epub ahead of print).
- Scheltens P , van der Pol L. Atrophy of medial temporal lobes on MRI in ‘probable‘ Alzheimer‘s disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatr.83(11), 1038–1040 (2012).
- Resnick SM , ScheltensP. MRI-based biomarkers of preclinical AD: an Alzheimer signature. Neurology78(2), 80–81 (2012).
- Greenberg BM , FrohmanE. Optical coherence tomography as a potential readout in clinical trials. Ther. Adv. Neurol. Disord.3(3), 153–160 (2010).
- Dudley JT , ButteAJ. Identification of discriminating biomarkers for human disease using integrative network biology. Pac. Symp. Biocomput.27–38 (2009).
- Suthram S , DudleyJT, ChiangAP, ChenR, HastieTJ, ButteAJ. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput. Biol.6(2), e1000662 (2010).
- Gauthier S . Will CSF analysis become routine in people with memory complaints? Lancet Neurol.8(7), 595–596 (2009).